Back to Search Start Over

Efficacy of the In2Care® auto-dissemination device for reducing dengue transmission: study protocol for a parallel, two-armed cluster randomised trial in the Philippines

Authors :
Ariza Aguila
Marianette T. Inobaya
Ava Kristy Sy
Edward K. Thomsen
Jason R. Angeles
Michael J. Bangs
Ferdinand V. Salazar
Richard Paul
Tom Toner
Research Institute for Tropical Medicine [Muntinlupa City, Philippines]
Liverpool School of Tropical Medicine (LSTM)
Kasetsart University - KU (THAILAND)
Kasetsart University (KU)
PT Freeport Indonesia/International SOS
Génétique fonctionnelle des maladies infectieuses - Functional Genetics of Infectious Diseases
Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris]
Génomique évolutive, modélisation et santé (CNRS-UMR2000)
Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)
This study was funded by the Agence Française de Développement in the context of the Ecomore 2 programme ( www.ecomore.org/ ). The funding body did not have any role in project design or in the writing of this manuscript. The trial sponsor is Institut Pasteur, Paris, France.
Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)
Génomique évolutive, modélisation et santé (GEMS)
Source :
Trials, Trials, BioMed Central, 2019, 20 (1), pp.269. ⟨10.1186/s13063-019-3376-6⟩, Trials, Vol 20, Iss 1, Pp 1-12 (2019), Trials, 2019, 20 (1), pp.269. ⟨10.1186/s13063-019-3376-6⟩
Publication Year :
2019
Publisher :
HAL CCSD, 2019.

Abstract

Background Mosquito-borne viruses are imposing an ever increasing health burden worldwide. In addition to the recent Zika and chikungunya virus epidemics, dengue viruses have become the fastest growing problem with a 40-fold increase in the number of reported cases over the past five decades. Current mosquito control techniques involving larval source reduction, larviciding, and space spray of adulticides are costly, laborious, and of debatable efficacy. There remains an urgent need for the development of intervention methods that can be reasonably implemented in the context of modern day urbanisation. Auto-dissemination (AD) of insecticide by adult mosquitoes offers a potentially practical and useful tool in an integrated vector control programme. Recently, an immediately employable AD device, the In2Care® mosquito trap, has been commercialised and shows promise as an effective tool. However, there remains a lack of demonstration of epidemiological efficacy. Methods/design This trial aims to assess the extent to which implementation of In2Care® mosquito traps can reduce vector Aedes (Stegomyia) spp. adult mosquito densities and dengue virus transmission as measured by sequential sero-conversion rates in children 6–16 years of age in a dengue endemic location: Lipa City, Philippines. To achieve this, we will carry out a parallel, two-armed cluster randomised trial evaluating AD efficacy for reducing the incidence of dengue over a 2-year period with 4 consecutive months of vector control during peak dengue transmission each year. Discussion For decades, it has been commonly accepted that an integrated approach to mosquito control is required. The World Health Organization (WHO) Global Strategic Framework for Integrated Vector Management recommends a range of interventions, in combination, to increase control impact to reduce transmission. This efficacy trial of the first commercial product using the AD approach will be informative in assessing the general utility of AD in reducing not only adult vector densities but, more importantly, reducing the incidence of dengue. The AD technique may complement source reduction and larviciding campaigns by more efficiently targeting the most productive containers and those beyond human reach. If successful, this mosquito control strategy could prove an invaluable tool in the fight against urban mosquito vectors and a reduction in the burden of associated disease. Trial registration ISRCTN44272773. Registered on 31 January 2019. Electronic supplementary material The online version of this article (10.1186/s13063-019-3376-6) contains supplementary material, which is available to authorized users.

Details

Language :
English
ISSN :
17456215
Database :
OpenAIRE
Journal :
Trials, Trials, BioMed Central, 2019, 20 (1), pp.269. ⟨10.1186/s13063-019-3376-6⟩, Trials, Vol 20, Iss 1, Pp 1-12 (2019), Trials, 2019, 20 (1), pp.269. ⟨10.1186/s13063-019-3376-6⟩
Accession number :
edsair.doi.dedup.....c25f5ee3f6fb84d9608d9c14645bcccf